ENDOLOGIX, INC. (a Delaware corporation) 3.25% Convertible Senior Notes due 2020 UNDERWRITING AGREEMENTUnderwriting Agreement • October 29th, 2015 • Endologix Inc /De/ • Surgical & medical instruments & apparatus • New York
We have served as intellectual property counsel for TriVascular, Inc. (“TriVascular” or the “Company”), a wholly-owned subsidiary of TriVascular Technologies, Inc., with respect to certain intellectual property matters relating to endoluminal stent grafts and their associated delivery systems, which are both used for the treatment of abdominal aortic aneurysms (“AAA”). We are issuing this opinion pursuant to Section 5(e) of that certain Underwriting Agreement between Endologix, Inc. and Piper Jaffray & Co., dated October 27, 2015 (the “Agreement”), at the request of the Company. All statements and opinions in this letter are expressly limited to the matters listed in Schedule A, attached, and shall not be construed to extend to any other matters. We have represented the Company only with respect to certain intellectual property matters. The scope of this opinion is limited accordingly.
